Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F17%3A43889305" target="_blank" >RIV/60162694:G44__/17:43889305 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/17:10365830

Result on the web

<a href="http://www.cmaj.ca/content/189/41/E1276" target="_blank" >http://www.cmaj.ca/content/189/41/E1276</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1503/cmaj.161288" target="_blank" >10.1503/cmaj.161288</a>

Result language

angličtina

Original language name

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

Original language description

BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12-24 months of age received a booster at 4 years of age. Vaccine-naive age-matched toddlers received 2 doses of 4CMenB. Human serum bactericidal antibody titres against reference strains H44/76, 5/99, NZ98/254 and M10713 were evaluated before and after innoculation with 4CMenB vaccine in 4-year-old children. RESULTS: Of 332 children in the study, 123 had previously received 4CMenB and 209 were vaccine-naive controls. Before the booster, the proportions of participants (previously vaccinated groups compared with controls) with hSBA titres of 1:5 or more were as follows: 9%-11% v. 1% (H44/76), 84%-100% v. 4% (5/99), 0%-18% v. 0% (NZ98/254) and 59%-60% v. 60% (M10713). After 1 dose of 4CMenB in previously immunized children, the proportions of participants achieving hSBA titres of 1:5 or more were 100% (H44/76 and 5/99), 70%-100% (NZ98/254) and 90%-100% (M10713). INTERPRETATION: We found that waning of hSBA titres by 4 years of age occurred after 2 doses of 4CMenB vaccine administered at 12-24 months, and doses at 12-24 months have a priming effect on the immune system. A booster may be necessary to maintain hSBA titres of 1:5 or more among those children with increased disease risk. Trial registration: ClinicalTrials.gov, no. NCT01717638

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30302 - Epidemiology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Canadian Medical Association Journal

ISSN

0820-3946

e-ISSN

—

Volume of the periodical

189

Issue of the periodical within the volume

41

Country of publishing house

CA - CANADA

Number of pages

10

Pages from-to

"E1276"-"E1285"

UT code for WoS article

000413572900003

EID of the result in the Scopus database

2-s2.0-85032512763